Evidence map›Paper›PMID 36460710›Full record

ArticleScientific reports2022

SARS-CoV-2 spike protein induces a differential monocyte activation that may contribute to age bias in COVID-19 severity.

Ines Ait-Belkacem, Celia Cartagena García, Ewa Millet-Wallisky, Nicolas Izquierdo, Marie Loosveld, Isabelle Arnoux, Pierre-Emmanuel Morange, Franck Galland, Nathalie Lambert, Fabrice Malergue and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Variants rs3804099 and rs3804100 in theInternational journal of molecular sciences · 2024
    Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Ines Ait-Belkacem *Department of Research and Development, Beckman Coulter Life Sciences-Immunotech, Marseille, France.
Celia Cartagena García *Department of Research and Development, Beckman Coulter Life Sciences-Immunotech, Marseille, France.
Ewa Millet-WalliskyDepartment of Research and Development, Beckman Coulter Life Sciences-Immunotech, Marseille, France.
Nicolas IzquierdoDepartment of Research and Development, Beckman Coulter Life Sciences-Immunotech, Marseille, France.
Marie LoosveldHematology Laboratory, Timone University Hospital, APHM, Marseille, France.
Isabelle ArnouxHematology Laboratory, Timone University Hospital, APHM, Marseille, France.
Pierre-Emmanuel MorangeHematology Laboratory, Timone University Hospital, APHM, Marseille, France.
Franck GallandAix Marseille Université CNRS INSERM CIML Centre d'Immunologie de Marseille-Luminy, Marseille, France.
Nathalie LambertINSERM UMRs 1097, Aix Marseille University, Marseille, France.
Fabrice MalergueDepartment of Research and Development, Beckman Coulter Life Sciences-Immunotech, Marseille, France. fmalergue@beckman.com.
Jean-Marc BusnelDepartment of Research and Development, Beckman Coulter Life Sciences-Immunotech, Marseille, France. jmbusnel@beckman.com.
Inserm · FRAix-Marseille Université · FRCentre d’Immunologie de Marseille-Luminy · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A strong bias related to age is observed in COVID-19 patients with pediatric subjects developing a milder disease than adults. We hypothesized that a specific SARS-CoV-2 effect conjugated with preexisting differences in the immune systems may explain this. Using flow cytometry, we investigated basal immune differences in a cohort consisting of 16 non-infected young and 16 aged individuals and further leveraged an in vitro whole blood model of SARS-CoV-2 infection so that functional differences could be mined as well. In short, blood diluted in culture media was incubated 5 or 24 h with the trimeric spike protein or controls. Following unsupervised analysis, we first confirmed that the immune lymphoid and myeloid systems in adults are less efficient and prone to develop higher inflammation than those in children. We notably identified in adults a higher CD43 lymphocyte expression, known for its potentially inhibitory role. The spike protein induced different responses between adults and children, notably a higher increase of inflammatory markers together with lower monocyte and B cell activation in adults. Interestingly, CD169, a CD43 ligand overexpressed in COVID-19 patients, was confirmed to be strongly modulated by the spike protein. In conclusion, the spike protein exacerbated the preexisting lower immune responsiveness and higher inflammatory potential in adults. Altogether, some of the markers identified may explain the marked age bias and be predictive of severity.

Indexed as

COVID-19MonocytesSpike Glycoprotein, CoronavirusAdultAgedChildHumansSARS-CoV-2Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID36460710
PMCPMC9716544
OpenAlexW4311114023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.